Pomalidomide plus rituximab maintenance for high-risk DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether a combination of two drugs (pomalidomide and rituximab) can help prevent lymphoma from coming back after initial treatment. It is for younger patients with high-risk DLBCL who responded well to their first therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 59 years old.
- You must have been diagnosed with DLBCL and have had at least a partial response to your first treatment.
- You must have had stage II, III, or IV lymphoma at diagnosis.
- You must not have another active cancer, a history of blood clots, or serious heart, liver, or kidney problems.
- You must not be pregnant or breastfeeding, and must use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pomalidomide, rituximab, and an immunotherapy called anti-PD-1) for people with diffuse large B-cell lymphoma that has not responded or has come back after two prior treatments. The goal is to see if this combination can help control the lymphoma.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests a three-drug combination (pomalidomide, an anti-CD20 antibody, and prednisone) to treat certain slow-growing B-cell lymphomas that have never been treated before. The goal is to see if this combination works better than standard approaches.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.